mepolizumab nct02105948 (Metrex Inc)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Metrex Inc mepolizumab nct02105948
Mepolizumab Nct02105948, supplied by Metrex Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nct02105948/mepolizumab/pmc09218150-63-10-11
Average 90 stars, based on 1 article reviews

mepolizumab nct02105948 - by Bioz Stars, 2026-09

90/100 stars

Images

other:

Article Title: Anti-IL-5 therapies for chronic obstructive pulmonary disease
Article Snippet: NCT02105948 (METREX) (Continued) Study characteristics Methods Multicentre, phase 3, randomised, placebo-controlled, double-blind, parallel-group study Study locations: Argentina, Australia, Canada, Chile, Denmark, Germany, Japan, Republic of Korea, the Netherlands, Romania, Slovakia, Taiwan, Ukraine, the United Kingdom, the United States Study duration: 52 weeks Participants 674 participants aged at least 40 years with COPD.

Article Title: Anti-IL-5 therapies for chronic obstructive pulmonary disease
Article Snippet: Participants in Dasgupta 2016 were current or former smokers, whereas in NCT02105948 (METREX) and NCT02105961 (METREO) participation was independent of smoking status and smoking history.

Article Title: Anti-IL-5 therapies for chronic obstructive pulmonary disease
Article Snippet: Time Frame: baseline and Week 52 NCT02105948 (METREX) (Continued) Anti-IL-5 therapies for chronic obstructive pulmonary disease (Review) Copyright © 2020 The Cochrane Collaboration.

Article Title: Anti-IL-5 therapies for chronic obstructive pulmonary disease
Article Snippet: D I S C U S S I O N Summary of main results Six studies met the inclusion criteria for this review (Brightling 2014; Dasgupta 2016; NCT02105948 (METREX); NCT02105961 (METREO); NCT02138916 (GALATHEA); NCT02155660 (TERRANOVA)).

Comparison:

Article Title: Anti-IL-5 therapies for chronic obstructive pulmonary disease
Article Snippet: .. E?ects of interventions See: Summary of findings 1 Mepolizumab 100 mg compared with placebo for chronic obstructive pulmonary disease; Summary of findings 2 Mepolizumab 300 mg compared with placebo for chronic obstructive pulmonary disease; Summary of findings 3 Mepolizumab 750 mg compared with placebo for chronic obstructive pulmonary disease; Summary of findings 4 Benralizumab 10 mg compared with placebo for chronic obstructive pulmonary disease; Summary of findings 5 Benralizumab 30 mg compared with placebo for chronic obstructive pulmonary disease; Summary of findings 6 Benralizumab 100 mg compared with placebo for chronic obstructive pulmonary disease Mepolizumab 100 mg versus placebo Primary outcomes All exacerbations The two trials NCT02105961 (METREO) and NCT02105948 (METREX) providing data to this comparison reported their results for participants with higher levels of blood eosinophils (defined as ≥ 150 cells per mm3 at screening or ≥ 300 cells per mm3 in the year before trial entry) separately and their total sample. ..

Article Title: Anti-IL-5 therapies for chronic obstructive pulmonary disease
Article Snippet: Comparison 1: Mepolizumab 100 mg versus placebo, Outcome 3: Rate of exacerbations with ED visit or hospitalisation Study or Subgroup 1.3.1 Eosinophilic phenotype NCT02105948 (METREX) NCT02105961 (METREO) Subtotal (95% CI) Heterogeneity: Chi2 = 3.98, df = 1 (P = 0.05); I2 = 75% Test for overall effect: Z = 0.66 (P = 0.51) 1.3.2 All participants NCT02105948 (METREX) NCT02105961 (METREO) Subtotal (95% CI) Heterogeneity: Chi2 = 4.07, df = 1 (P = 0.04); I2 = 75% Test for overall effect: Z = 0.47 (P = 0.64) Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 = 0% log[Rate Ratio] 0.1484 -0.5276 0.0953 -0.5276 SE 0.2091 0.2664 0.1561 0.2664 Mepolizumab Total 233 223 456 417 223 640 Placebo Total 229 226 455 419 226 645 Weight 61.9% 38.1% 100.0% 74.4% 25.6% 100.0% Rate Ratio IV, Fixed, 95% CI 1.16 [0.77 , 1.75] 0.59 [0.35 , 0.99] 0.90 [0.65 , 1.24] 1.10 [0.81 , 1.49] 0.59 [0.35 , 0.99] 0.94 [0.72 , 1.22] Rate Ratio IV, Fixed, 95% CI 0.5 0.7 1 1.5 2 Favours mepolizumab Favours placebo Analysis 1.4. .. Comparison 1: Mepolizumab 100 mg versus placebo, Outcome 4: Serious adverse events Study or Subgroup NCT02105948 (METREX) NCT02105961 (METREO) Total (95% CI) Total events: Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.85); I2 = 0% Test for overall effect: Z = 1.57 (P = 0.12) Test for subgroup differences: Not applicable Mepolizumab Events 115 57 172 Total 417 223 640 Placebo Events 131 68 199 Total 419 226 645 Weight 65.3% 34.7% 100.0% Odds Ratio M-H, Fixed, 95% CI 0.84 [0.62 , 1.13] 0.80 [0.53 , 1.21] 0.82 [0.65 , 1.05] Odds Ratio M-H, Fixed, 95% CI 0.2 0.5 1 2 5 Favours mepolizumab Favours placebo Anti-IL-5 therapies for chronic obstructive pulmonary disease (Review) Copyright © 2020 The Cochrane Collaboration. ..

Article Title: Anti-IL-5 therapies for chronic obstructive pulmonary disease
Article Snippet: Comparison 1: Mepolizumab 100 mg versus placebo, Outcome 1: Rate of moderate or severe exacerbations Study or Subgroup 1.1.1 Eosinophilic phenotype NCT02105948 (METREX) NCT02105961 (METREO) Subtotal (95% CI) Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 = 0% Test for overall effect: Z = 2.95 (P = 0.003) 1.1.2 All participants NCT02105948 (METREX) NCT02105961 (METREO) Subtotal (95% CI) Heterogeneity: Chi2 = 2.50, df = 1 (P = 0.11); I2 = 60% Test for overall effect: Z = 1.42 (P = 0.16) Test for subgroup differences: Chi2 = 1.80, df = 1 (P = 0.18), I2 = 44.4% log[Rate Ratio] -0.1985 -0.2231 -0.0202 -0.2231 SE 0.0955 0.1059 0.0726 0.1059 Mepolizumab Total 233 223 456 417 223 640 Placebo Total 229 226 455 419 226 645 Weight 55.2% 44.8% 100.0% 68.0% 32.0% 100.0% Rate Ratio IV, Fixed, 95% CI 0.82 [0.68 , 0.99] 0.80 [0.65 , 0.98] 0.81 [0.71 , 0.93] 0.98 [0.85 , 1.13] 0.80 [0.65 , 0.98] 0.92 [0.82 , 1.03] Rate Ratio IV, Fixed, 95% CI 0.2 0.5 1 2 5 Favours mepolizumab Favours placebo Analysis 1.2. .. Comparison 1: Mepolizumab 100 mg versus placebo, Outcome 2: Time to first moderate or severe exacerbation Study or Subgroup 1.2.1 Eosinophilic phenotype NCT02105948 (METREX) NCT02105961 (METREO) Subtotal (95% CI) Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 = 0% Test for overall effect: Z = 2.93 (P = 0.003) 1.2.2 All participants NCT02105948 (METREX) NCT02105961 (METREO) Subtotal (95% CI) Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.59); I2 = 0% Test for overall effect: Z = 1.99 (P = 0.05) Test for subgroup differences: Chi2 = 0.89, df = 1 (P = 0.35), I2 = 0% log[Hazard Ratio] -0.2877 -0.1985 -0.1165 -0.1985 SE 0.1139 0.1264 0.0873 0.1264 Mepolizumab Total 233 223 456 417 223 640 Placebo Total 299 226 525 419 226 645 Weight 55.2% 44.8% 100.0% 67.7% 32.3% 100.0% Hazard Ratio IV, Fixed, 95% CI 0.75 [0.60 , 0.94] 0.82 [0.64 , 1.05] 0.78 [0.66 , 0.92] 0.89 [0.75 , 1.06] 0.82 [0.64 , 1.05] 0.87 [0.75 , 1.00] Hazard Ratio IV, Fixed, 95% CI 0.5 0.7 1 1.5 2 Favours mepolizumab Favours placebo Anti-IL-5 therapies for chronic obstructive pulmonary disease (Review) Copyright © 2020 The Cochrane Collaboration. ..

Review

mepolizumab nct02105948 (Metrex Inc)

Structured Review

Images

Related Articles

other:

Comparison:

Similar Products

Image Search Results